key: cord-0753480-h91bqoxo
authors: Dal-Ré, Rafael; Stephens, Richard; Sreeharan, Nadarajah
title: “Let me choose my COVID-19 vaccine”
date: 2021-02-04
journal: Eur J Intern Med
DOI: 10.1016/j.ejim.2021.01.030
sha: b8d8739b21aa61b30e521a42c764abf112d12454
doc_id: 753480
cord_uid: h91bqoxo

nan

Although an individual's decision to be vaccinated will be voluntary, the choice of vaccine they receive will not. The paternalistic physician/patient relationship has long ago been replaced by a patient-centered approach in which values and preferences of patients are critical for therapeutic decisions [4, 5] . However, this model has generally not been applied for the deployment of either pediatric or adult vaccines, where parents and individuals are expected to accept the paternalistic approach of governments and whichever vaccine is provided by the NHS. This is so because vaccines are usually purchased through public tenders in which governments buy the most cost-effective vaccine fulfilling certain specifications. But this will not be the case with the availability of several distinctly different COVID-19 vaccines.

Considerable anxiety and fear prevail with significant adverse impact of COVID-19 on mortality, mental well-being and the economy of the population; therefore, whenever possible, a flexible individual-centric approach should be undertaken. Participation of the individual in the decision-making process will only help to enhance trust and diminish vaccine hesitancy.

Vaccine efficacy, safety, platform type, number of shots, and price paid by the state [6] could be relevant factors influencing choice for many people. In this respect, it would be reasonable that those individuals who are aware that, for instance, a specific vaccine has not had time to show yet efficacy data in a given population group ─as happens with the AstraZeneca vaccine in older adults (≥56-year-old individuals) [7] ─ could have the chance to be vaccinated with a different vaccine that has showed sufficient efficacy data [8, 9] . We recognize the operational complexity of such an approach for vaccine deployment and administration. But if the aim is to vaccinate the vast majority of citizens [10] , perhaps offering flexibility towards individual autonomy will help facilitate this objective.

We suggest a flexible approach where most of the population will be offered and probably accept the vaccine provided by the NHS. However, when possible and as a respect for individual values and preferences, any citizen should be entitled to discuss their preferred vaccine with the healthcare provider. This would enhance public confidence and likely increase vaccine uptake, which should be the goal of any vaccination campaign.

This work required no funding

None declared.

The views or opinions presented in this manuscript are solely those of the authors and do not necessarily represent those of the institutions or organizations they work with or for.

Global attitudes on a COVID-19 vaccine. Ipsos survey for The World Economic Forum

European Medicines Agency. Extra transparency measures for COVID-19 vaccines and therapeutics

WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines

Patient-centered medicine. A professional evolution

People-Centred Health Care. Technical papers. International symposium on peoplecentred health care: reorienting health systems in the 21 st century

Belgian minister tweets EU's Covid vaccine price list to anger manufacturers. The Guardian

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Communication from the Commission to the European Parliament and the Council